NPI: 1275810905 · TAMPA, FL 33618 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 11/09/2011
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP,LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 11/09/2011 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,105 | $569K |
| 2019 | 12,454 | $1.05M |
| 2020 | 16,527 | $1.91M |
| 2021 | 13,733 | $1.44M |
| 2022 | 8,356 | $992K |
| 2023 | 853 | $124K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 17,502 | 1,205 | $2.16M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 19,543 | 809 | $1.75M |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,514 | 675 | $1.01M |
| A4657 | Syringe, with or without needle, each | 2,633 | 977 | $420K |
| J1756 | Injection, iron sucrose, 1 mg | 4,162 | 703 | $368K |
| 85041 | 962 | 575 | $98K | |
| 85048 | 957 | 573 | $97K | |
| 83970 | 419 | 211 | $34K | |
| 82728 | 323 | 205 | $32K | |
| 83550 | 322 | 205 | $32K | |
| 83540 | 322 | 205 | $32K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 245 | 97 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 93 | 68 | $6K |
| 82108 | 31 | 16 | $1K |